Drug Trial Radar · NCT06226129
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
150
Planned (sponsor's estimate)
Start
Feb 14, 2024
Primary completion
Feb 1, 2027
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guerbet
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.
Conditions
- Prostate Cancer
Interventions
GadopiclenolDrug
Gadopiclenol for contrast enhanced MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blinded Radiology Review of Enhancement of Images, Graded 1-5Time frame: Through Study Completion (An Average of 1 Year Post-MRI)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.